OK Biotech CoTPE:4155 61 EBITDA Margin % is 29.60% as of Dec. 2025, which is 101% above its 10-year median of 14.74. GuruFocus rates TPE:4155 with a GF Score™ of 61/100 and a GF Value™ of NT$27.27 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, OK Biotech Co ranks better than 61.52% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. OK Biotech Co's EBITDA for the
three
months ended in Dec. 2025 was NT$100 Mil. OK Biotech Co's Revenue for the
three
months ended in Dec. 2025 was NT$338 Mil. Therefore, OK Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 29.60%.
OK Biotech Co (TPE:4155) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
OK Biotech Co EBITDA Margin % Related Terms
OK Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for OK Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4155 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, OK Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co (TPE:4155) has a EBITDA Margin % of 29.60% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OK Biotech Co and its competitors. This is 101% above median its historical median of 14.74. Over the past decade, OK Biotech Co's EBITDA Margin % has ranged from 7.77 to 21.17. According to the industry distribution chart, OK Biotech Co ranks #314 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 38.5%.
Is OK Biotech Co's EBITDA Margin % too high?
OK Biotech Co's current EBITDA Margin % of 29.60% is 101% above median its 10-year median of 14.74. Over the past 10 years, this metric has ranged from a low of 7.77 to a high of 21.17. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. OK Biotech Co's value of 29.60% is 296% above this industry median. Based on the distribution chart, OK Biotech Co ranks #314 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OK Biotech Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #314 out of 816 companies for EBITDA Margin %. This puts OK Biotech Co in the upper half of its industry. The industry median EBITDA Margin % is 7.48. OK Biotech Co's value of 29.60% is 296% above this benchmark. Historically, OK Biotech Co's own EBITDA Margin % has ranged from 7.77 to 21.17 over the past decade. While the company's 10-year median is 14.74 vs. the industry median of 7.48, OK Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current EBITDA Margin % of 29.60% is 296% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current EBITDA Margin % is 29.60%, which is 101% above median its own 10-year median of 14.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$27.27, compared to a current price of NT$15.00 — trading 45% below its estimated fair value. The current EBITDA Margin % is 29.60%, which is 101% above median its 10-year median of 14.74 and 296% above the Medical Devices & Instruments industry median of 7.48. OK Biotech Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current EBITDA Margin % is 29.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$15.00 is trading 45% below its estimated GF Value™ of NT$27.27.
GuruFocus considers OK Biotech Co to be Possible Value Trap.
Key valuation signals for TPE:4155:
EBITDA Margin %: 29.60% (101% above median its 10-year median of 14.74)
GF Value™: NT$27.27 vs. price of NT$15.00 (45% below fair value)
Industry Position: 296% above the Medical Devices & Instruments median (#314 of 816)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
61GF Score
Get the complete analysis for TPE:4155
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
